Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared
with placebo, on heart failure, disease specific biomarkers, symptoms, health status and
quality of life in patients with chronic heart failure with preserved systolic function.